Q3 2020 total revenues of $155.1 million, including net product sales of $152.1 million and royalty revenues of $3.0 million
Q3 2020 operating earnings of $56.1 million
On track to initiate commercial launch of SPN-812 in January 2021, if approved by the FDA
Topline data from the SPN-812 Phase III trial in adult ADHD patients expected in Q1 2021
Submitted SPN-830 (Apomorphine infusion pump) NDA to the FDA in September 2020
Increased full year 2020 net product sales guidance range of $500 million to $525 million, and operating earnings guidance range of $145 million to $160 million
See our SUPN AmpCards to learn more.